1. Home
  2. Products
  3. Customized ADCs
  4. EGFR
  5. Anti-EGFR-EDC/NHS-Dox ADC

Anti-EGFR-EDC/NHS-Dox ADC (CAT#: ADC-W-503)

This ADC product is comprised of an anti-EGFR monoclonal antibody conjugated via a EDC/NHS linker to Dox. The Dox is targeted to certain cancers by immunerecognition and delivered into cancer cells via receptor mediated endocytosis. Within the cell, Dox binds to DNA, causes DNA damage.

  • ADC Target
  • ADC Antibody
  • ADC Linker
  • ADC payload drug
  • Name
  • EGFR
  • Alternative Names
  • epidermal growth factor receptor; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2; proto-oncogene c-ErbB-1; cell growth inhibiting protein 40; erb-b2 receptor tyrosine kinase 1; cell proliferation-inducing protein 61; receptor tyrosine-protein kinase erbB-1; avian
  • Target Entrez Gene ID
  • 1956
  • Overview
  • The protein encoded by this gene is a transmembrane glycoprotein that is a member of the protein kinase superfamily. This protein is a receptor for members of the epidermal growth factor family. EGFR is a cell surface protein that binds to epidermal growth factor. Binding of the protein to a ligand induces receptor dimerization and tyrosine autophosphorylation and leads to cell proliferation. Mutations in this gene are associated with lung cancer. Multiple alternatively spliced transcript variants that encode different protein isoforms have been found for this gene.
  • Overview
  • Chimeric Anti-EGFR lgG1 Antibody
  • Species Reactivity
  • Human
  • Name
  • EDC/NHS(1-ethyl-3-(3-diaminopropyl)carbodiimide/N-hydroxysuccinimide)
  • Description
  • Acid-labile linkers, belonging to chemically cleavable linkers, are designed based on a pH-dependent release mechanism and remain intact during systemic circulation in the blood's neutral pH environment (pH 7.3–7.5) but to undergo hydrolysis and release drug once the ADC is internalized into mildly acidic endosomal (pH 5.0–6.5) and lysosomal (pH 4.5–5.0) compartments of the cell.
  • Name
  • Doxorubicin
  • Description
  • Doxorubicin is a type of anti-cancer chemotherapy drug called an anthracycline. Doxorubicin works by blocking an enzyme called TopoisomeraseⅡthat cancer cells need to divide and grow.

Published Data

+ Submit Publications

Submit a review or a question

Scientific Resources

Customer Reviews and FAQs

There are currently no Customer reviews or questions for ADC-W-503. Click the button above to contact us or submit your feedback about this product.

Quick Links

Other Products

Same Target Same Linker Same Payload
CAT# Product Name Linker Payload
ADC-W-2592 Anti-EGFR (Cetuximab)-MC-Vc-PAB-MMAE ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) MMAE
ADC-W-505 Anti-EGFR (cetuximab)-EDC/NHS-methotrexate ADC EDC/NHS(1-ethyl-3-(3-diaminopropyl)carbodiimide/N-hydroxysuccinimide) methotrexate (MTX)
ADC-W-2587 Anti-EGFR (Zalutumumab)-MC-Vc-PAB-SN38 ADC MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) SN-38 (7-ethyl-10-hydroxycamptothecin)
ADC-W-2585 Anti-EGFR (Zalutumumab)-MC-MMAF ADC MC (maleimidocaproyl) MMAF
ADC-W-504 Anti-EGFR (cetuximab)-SMCC-Doxorubicin ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) Doxorubicin
CAT# Product Name Linker Payload
ADC-W-505 Anti-EGFR (cetuximab)-EDC/NHS-methotrexate ADC EDC/NHS(1-ethyl-3-(3-diaminopropyl)carbodiimide/N-hydroxysuccinimide) methotrexate (MTX)
CAT# Product Name Linker Payload
ADC-W-340 Anti-TNFRSF8-DIBO-doxorubicin ADC-12 DIBO (dibenzylcyclooctynol) doxorubicin
ADC-W-479 Anti-CD74-SMCC-Dox ADC SMCC (N-succinimidyl 4-(Nmaleimidomethyl)cyclohexane-1-carboxylate) Doxorubicin
ADC-W-571 Anti-ERBB2 (Trastuzumab)-DOX ADC thiomaleamicacids-p-aminobenzyloxycarbonyl doxorubicin
ADC-W-578 Anti-CD74-MCC-Dox ADC MCC (Maleimidomethyl cyclohexane-1-carboxylate) doxorubicin
ADC-W-339 Anti-CD22-DIBO-doxorubicin ADC DIBO (dibenzylcyclooctynol) doxorubicin

For Research Use Only. NOT FOR CLINICAL USE.

Online Inquiry

Name:
Phone:
*E-mail Address:
*Products or Services Interested:
Company/Institution
Project Description:

Welcome! For price inquiries, please feel free to contact us through the form on the left side. We will get back to you as soon as possible.